Cyprotex PLC Launch of new eCiphrNeuro service
July 18 2013 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
18 July 2013
Cyprotex to launch eCiphrNeuro,
a new service to evaluate neuronal activity
18 July, 2013 - Cyprotex PLC (AIM:CRX), a specialist ADME-Tox
Contract Research Organisation, today extends its eCiphr range with
the launch of a new service, eCiphrNeuro, using microelectrode
array (MEA) technology to monitor the electrical activity of
neurons and assess potential neurotoxic or neuro-efficacious
effects of new drug candidates.
Neurotoxicity continues to be a significant toxicological reason
for drug attrition. eCiphrNeuro provides an early stage solution
for identifying potentially adverse effects of new chemicals on
neuronal integrity and function. The service utilises the Maestro
MEA system from Axion Biosystems ("Axion"), which has proven to be
a robust, high-throughput platform to test for drug effects on
clinically-relevant neuronal and cardiac electrophysiological
features.
eCiphrNeuro complements Cyprotex's existing CellCiphr(R) Premier
and eCiphrCardio assays, which are used to screen compounds for
potential drug-induced hepatotoxicity and cardiotoxicity,
respectively.
Dr. Anthony Baxter, the Chief Executive Officer of Cyprotex,
said: "Cyprotex continues to lead the way in novel in vitro
approaches to address drug-induced toxicities. eCiphrNeuro
complements our comprehensive portfolio of assays developed to
resolve potential toxicity concerns early in the drug development
process. Although the primary purpose of developing this service
was to identify potential neurotoxicity of compounds, the assay can
also be applied to efficacy testing for CNS-related projects."
Tom O'Brien, President and Chief Executive Officer of Axion,
added: "With the introduction of eCiphrNeuro, Cyprotex is the first
company to offer a neurotoxicity assay using our high throughput
microelectrode array (MEA) platform. Given the MEA's proven
capability for monitoring in vitro networks, this assay provides
scientists with an unparalleled opportunity to rapidly screen
compounds for their functional effects on complex neural systems.
We look forward to working with the Cyprotex team as they continue
to expand their portfolio of cellular electrophysiology assays
utilising Axion's Maestro MEA system."
To find out more about this service, visit:
http://www.cyprotex.com/toxicology/neurotoxicity/eciphrneuro/
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505
100
Dr Anthony Baxter, Chief Executive Officer ir@cyprotex.com
John Dootson, Chief Financial Officer www.cyprotex.com
Mark Warburton, Chief Operating Officer
and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex) Tel: +44 (0)20 7496
3000
Shaun Dobson shaun.dobson@n1singer.com
Jenny Wyllie jenny.wyllie@n1singer.com
www.n1singer.com
FTI Consulting Tel: +44 (0) 20 7831
3113
Simon Conway cyprotex@fticonsulting.com
Mo Noonan www.fticonsulting.com
Notes to Editors
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK,
and Watertown, MA in the US and is listed on the AIM market of the
London Stock Exchange (CRX). The company was established in 1999
and works with more than 700 partners ranging from small biotechs
to large pharma companies. Cyprotex acquired Apredica and the
assets of Cellumen Inc. in August 2010 and the combined business
provides support for a wide range of experimental and computational
ADME-Tox and PK services, extending from early drug discovery
through to IND submission. The company's core capabilities include
high quality in vitro ADME screening services, mechanistic
toxicology and high content toxicology screening services and
predictive modelling using PBPK and QSAR techniques. For more
information, see www.cyprotex.com.
About Axion BioSystems, Inc.
Axion BioSystems, Inc. is a life science instrumentation company
that develops high-throughput microelectrode array (MEA) systems
for in vitro network electrophysiology, allowing researchers to
model neural activity and cardiac beating. As a result, toxicity
and efficacy can be assessed earlier in the drug development
process with greater sensitivity and accuracy. For more
information, see www.axionbiosystems.com.
Further information on eCiphrNeuro
eCiphrNeuro is an in vitro assay used to screen compounds to
detect potential effects on neuronal function. The assay has been
validated with primary neurons, which are analysed on Axion
BioSystem's Maestro MEA system. The MEA Maestro system has proven
to be a robust, high-throughput system to test for drug effects on
a number of clinically-relevant neuronal electrophysiological
features.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALDLLFXDFBBBD
Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024